January 19, 2006

Skinvisible’s ‘Chlorhexidine Hand Sanitizer’ 99% Proven Effective against Avian ‘Bird Flu’

Contacts:
Ronald Trahan, APR, President Ronald Trahan Associates Inc., 508-816-6730

Terry Howlett, President/CEO Skinvisible, Inc., 702-433-7154 (after hours: 702-521-1919)

Study by Retroscreen Virology, subsidiary of Univ. of London's Queen Mary School of Medicine, shows Skinvisible's patent-pending Chlorhexidine Hand Sanitizer is more than 99 percent effective at killing the avian 'bird flu' virus H5N1 within seconds of contact

Product's patented delivery system, Invisicare, ensures coverage for four hours, while resisting wash-off during that time

Data to be presented at Retroscreen Virology Conference - “Bird Flu: The First Pandemic of the 21st Century”

“The high probability of a bird flu pandemic underscores the dire need to prevent any opportunities of transmission of the virus between avian species and humans. An effective, long-lasting sanitizer is ideal for use in poultry farms or quarantine units to prevent transmission of the virus. In addition, healthcare workers, research scientists and those handling infected animals also would benefit from such a sanitizer against the H5N1 virus.”
Terry Howlett President and CEO Skinvisible, Inc.

LAS VEGAS, Nev., and LONDON, Jan. 19, 2006 — Skinvisible, Inc. (OTC Bulletin Board: 'SKVI' / Website: www.skinvisible.com) announced today that a study by Retroscreen Virology of Skinvisible's patent-pending Chlorhexidine Hand Sanitizer, developed by its wholly owned subsidiary, Skinvisible Pharmaceuticals, had a greater than 99 percent kill on the 'Bird Flu Virus' (H5N1) at 4 time points of 15 seconds, 30 seconds, 1 minute and 5 minutes. In vitro studies demonstrate a sustained release of the active ingredient over a 6-hour period. The study's results will be reported by Skinvisible at the upcoming Retroscreen Virology conference, “Bird Flu: The First Pandemic of the 21st Century,” which begins today at St. Bartholomew's Hospital, London.

The active ingredient in Skinvisible's product is Chlorhexidine (klor-HEX-i-deen), an easily tolerated and effective antiseptic that kills or inhibits the growth of disease-causing bacteria, viruses and other microorganisms, and is used for surgical scrub, skin wounds, germicidal hand rinse, and antibacterial dental rinse. This compound is delivered via Skinvisible's patented Invisicare delivery system. Skinvisible has applied for a patent using the combination of Chlorhexidine within the Invisicare polymer delivery system.

“The high probability of a bird flu pandemic underscores the dire need to prevent any opportunities of transmission of the virus between avian species and humans. An effective, long-lasting sanitizer is ideal for use in poultry farms or quarantine units to prevent transmission of the virus. In addition, healthcare workers, research scientists and those handling infected animals also would benefit from such a sanitizer against the H5N1 virus,” said Terry Howlett, President and CEO of Skinvisible, who will present the Retroscreen study results at the “Bird Flu...” conference.

“The avian flu virus can survive on human hands for several hours,” added Mr. Howlett. “The virus can also survive up to 48 hours on non-porous surfaces such as a telephone, computer keyboard, doorknobs, kitchen utensils and toys, for example. This is what makes hand-washing so important. Washing your hands frequently and using a product such as Skinvisible's Chlorhexidine Hand Sanitizer — which stays effective for up to four hours and cannot be rubbed off or washed off — could dramatically reduce the incidence of respiratory disease in general by 40 percent, experts say.”

“The World Health Organization has reported that a mutated form of the virus could kill 2 million to 7.4 million people, although some estimates are much higher,” continued Mr. Howlett. “We are seeking to broaden our marketing and distribution efforts in order to make our Chlorhexidine Hand Sanitizer available as soon as possible to the broadest market.” Globally, the influenza virus kills nearly one million people every year, and Skinvisible believes its Chlorhexidine Hand Sanitizer may offer an alternative to the alcohol-based hand sanitizers now used worldwide in the health care industry. Skinvisible's product has been tested against a variety of bacteria of concern to the health care industry, including the Super Bugs VRE and MRSA, as well as Clostridium Difficile. The product will be undergoing further tests soon against other viruses, including SARS, Influenza A (H1 and H3), as well as the B viruses.

About Invisicare

At the heart of Skinvisible's patented technology and trademarked Invisicare family of polymer delivery vehicles is its formula and process for combining hydrophilic and hydrophobic polymers into stable complexes in water emulsions. This allows formulated products using Invisicare as their platform to remain on the skin for extended periods of time, thereby affording active agents a prolonged timeframe to perform their intended functions. Products utilizing Invisicare have the proven ability to bond active ingredients to the skin for up to four or more hours. They are non-occlusive and allow normal skin respiration and perspiration while moisturizing and protecting against exposure from a wide variety of environmental irritants. When topically applied, these formulated products adhere to the skin's outer layers, forming a protective bond, resisting wash-off and delivering targeted levels of therapeutic or cosmetic skincare agents to the skin. They allow enhanced delivery performance for a variety of skincare agents resulting in improved efficacy, longer duration of action, reduced irritation and lower dosage of active agent required. The "invisible" polymer compositions wear off as part of the natural exfoliation process of the skin's outer layer cells.

About Retroscreen Virology Ltd.

London-based Retroscreen Virology is Europe's leading contract virology research company, created in 1989 from St. Bartholomew's Hospital and the Royal London Hospital by Professor John Oxford, a world-renowned influenza virologist. Retroscreen Virology, which specializes in laboratory and clinic-based respiratory virology research, is the only company in the UK that is able to conduct human influenza challenge studies in a specialized quarantine unit with A/Panama/2007/99 and A/New Caledonia/20/99 viruses, and has characterized influenza A (H1N1 and H3N2) and B viruses.

About Queen Mary College, University of London

Queen Mary College is the fourth-largest of the Colleges of the University of London, which also include Westfield College, St. Bartholomew's Hospital Medical College, and the London Hospital Medical College.

About Skinvisible Pharmaceuticals, Inc.

Headquartered in Las Vegas, Nevada, Skinvisible Pharmaceuticals is a research-and-development company that has formulated and patented innovative polymer delivery system technology and compositions for topical skin applications. Skinvisible's primary marketing and sales objective is to license its technology and sell its trademarked polymer delivery vehicles to established dermatological, cosmetic, skincare and pharmaceutical manufacturers.

Forward-Looking Statements

This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward-looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10QSB for the quarter ending September 30, 2005).



BACK TO:  News Index

Top